- Company
- 4th JAKi Cibinqo to be prescribed in general hospitals
- by Eo, Yun-Ho Jul 11, 2022 06:03am
- The fourth JAK inhibitor ‘Cibinqo ‘ has landed at general hospitals in Korea. According to industry sources, Pfizer Korea’s new Janus kinases (JAK) inhibitor ‘Cibinqo (abrocitinib)’ passed the drug committees (DCs) of various medical institutions in Korea, including the Seoul National University Hospital. The drug, which is approv
- Company
- ER contraceptive market battles over original & generics
- by Nho, Byung Chul Jul 11, 2022 06:03am
- Norevo (Levonorostrel 0.75mg) and Elaone (Ulipristal Acetate 30mg), which Hyundai Pharmaceutical received import licenses from HRA Pharma in 2001 and 2011, by a 10-year gap, are emerging as icons of changes in the emergency contraceptive market. Emergency contraceptives have been submitted to the Central Pharmaceutical Review Committee of the
- Company
- The pharmaceutical union of 2,500 people has been launched
- by Jul 11, 2022 06:03am
- The first chairman is Ahn Deok-hwan, head of the Korea Novartis union. Fifteen multinational companies and one domestic company participated in the NPU launch ceremony after three years of discussion "Working conditions are deteriorating despite increased sales in the pharmaceutical industry. Active response to common issues" The nation's
- Company
- Byung-Jae Yoo to head integrated Novartis Korea
- by Eo, Yun-Ho Jul 8, 2022 06:25am
- Byung-Jae Yoo (49) was appointed the head of the integrated Novartis Korea. Suhee Shin, General Manager of the Oncology Business Unit at Novartis submitted her resignation. According to industry sources, Novartis Korea has been integrating its Pharmaceuticals and Oncology Business Unit with the goal of completing the integration within th
- Company
- Dong-A ST prepares to make another leap with Actonel
- by Eo, Yun-Ho Jul 7, 2022 05:55am
- Dong-A ST is attempting to make another leap with ‘Actonel,’ a bisphosphonate drug that is now sold exclusively by the company. According to industry sources, Dong-A ST has been working to land Sanofi’s bisphosphonate osteoporosis treatment Actonel (risedronate) at major medical institutions in Korea after it started to exclusively sup
- Company
- Two pharmaceutical unions unite with each other
- by Jul 7, 2022 05:54am
- With the birth of the nation's largest pharmaceutical industry union, the number of unions affiliated with the Federation of Korean Trade Unions in the pharmaceutical industry has increased to two. This includes corporate unions that have withdrawn from the existing industrial unions, drawing keen attention to the background. The NPU was l
- Company
- First KRAS lung cancer drug Lumakras released next month
- by Jul 7, 2022 05:54am
- Non-small cell lung cancer patients with KRAS mutations are expected to be able to receive treatment with the targeted anticancer therapy ‘Lumakras (sotorasib)’ starting this August. Amgen announced it will actively increase diagnostic tests and pursue reimbursement listing for the drug to increase accessibility to the only KRAS-targeted thera
- Company
- Novonodisk labor union announces union struggle on 7th
- by Eo, Yun-Ho Jul 7, 2022 05:54am
- Novonodisk Pharmaceutical's labor union under the NPU will hold regular general meetings and fight for all members. Novonodisk labor union is currently fighting against ▲ wage negotiations broke down in 2021, ▲petition of the Ministry of Labor regarding wage arrears due to the change in the disadvantage of the sales department incentive sys
- Company
- Next-gen breast cancer drug, pneumococcal vaccine to come
- by Jul 6, 2022 05:47am
- New big drugs, including a pneumococcal vaccine, a macular degeneration treatment, and a breast cancer treatment, are expected to receive approval from the Ministry of Food and Drug Safety in the second half of this year. According to industry sources on the 6th, new drugs such as ▲Vaxneuvance (MSD) ▲Enhertu (Daiichi Sankyo) ▲Vabysmo (Roch
- Company
- BL’s COVID-19 treatment expands indication to pneumonia
- by Lee, Seok-Jun Jul 6, 2022 05:47am
- BL is aiming to adopt an indication expansion strategy and develop 'BLS-H01,’ its new drug for COVID-19 treatment for which a Phase II trial is underway, as a broad-spectrum treatment for pneumonia. According to BL on the 5th, BLS-H01 is an immunoregulatory treatment that contains a gamma PGA. A clinical trial is currently underway to ass
